腺病毒介导的环氧合酶-2反义RNA对肝癌细胞株生长的影响

目的探讨环氧合酶-2(COX-2)的表达与肝癌的关系,并构建表达人COX-2反义RNA的腺病毒载体,研究其对人肝癌细胞生长的抑制作用。方法采用免疫组织化学法探讨34例肝癌组织COX-2 的表达与肝癌病理特征的关系。采用基因重组法把人COX-2的cDNA片段反向克隆于穿梭质粒pHCMVSP1A,获得pAd-AShcox-2,通过脂质体与pJM17共转染293细胞,经同源重组产生编码COX-2反义RNA的重组腺病毒--Ad-AShcox-2。经聚合酶链反应法鉴定为阳性克隆者大量扩增、纯化,转染人肝癌细胞株SMMC-7402和SMMC-7721,采用免疫细胞化学、细胞集落形成率及流式细胞术检测其对肝癌细胞生长、凋亡及细胞周期分布的影响。结果34例肝癌组织中有28例COX-2高度表达,阳性率达82.4%; COX-2的表达水平与肝癌的病理分级有关,与甲胎蛋白、细胞类型、有无肝内转移无关。成功构建、扩增、纯化得到编码COX-2反义RNA的重组腺病毒Ad-AShcox-2,滴度达1.06×1012PFU/ml;Ad-AShcox- 2转染两种肝癌细胞株后,发现高度表达COX-2的SMMC-7402 COX-2表达水平明显降低,细胞凋亡率明显增加,出现G1期阻滞,与Ad-LacZ组及空白对照组比较差异有统计学意义(P<0.05);而不表达COX- 2的SMMC-7721变化不明显。细胞集落形成实验显示SMMC-7402细胞集落形成率较低(2.7%±0.94%); 而SMMC-7721     

Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells

Introduction The overexpression of the multidrug resistance gene 1 (mdr1), a product of multidrug resistance multidrug resistance, is a major obstacle in cancer chemotherapy. Being a major P-glycoproteincancer chemotherapy. Being a major P-glycoprotein (P-gp), 17 kDa transmembrane protein acts as an energy-dependent drug efflux pump and keeps the concentration and efficacy intracellular anticancer drugs low.[1-4] Hepatocellular carcinoma (HCC) represents more than 5% of all cancers in the w…     

环氧合酶-2反义RNA在不同时间点对食管癌细胞系EC9706生长的影响

目的:探讨环氧合酶-2(COX-2)反义RNA在不同时间点对人食管癌细胞系EC9706生长的影响。方法:培养293细胞,扩增、纯化COX-2反义RNk的重组腺病毒-Ad-AShcox-2,转染食管癌细胞EC9706,在不同时间点进行活细胞计数及3H-TdR掺入量测定。结果:扩增、纯化获得编码COX-2反义RNA的重组腺(?)毒Ad-AShcox-2,滴度达1.2×1012 PFU/ml;Ad-AShcox-2传染EC9706后在24 h、48 h、72 h、96 h对细胞生长的抑制率分别为8.60％、24.33％、50.21％、75.26％,对3H-TdR掺入量在24 h开始减少,以72～96 h最低,与对照组比较P<0.001。结论:表达COX-2反义RNA重组腺病毒感染人食管癌细胞后,对癌细胞的抑制从24 h开始,48～72 h最明显。     

Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells

AIM: To evaluate the effects of sulindac in inducing growth inhibition and apoptosis of human gastric cancer cells in comparison with human hepatocellular carcinoma (HCC) cells. METHODS: The human gastric cancer cell lines MKN45 and MKN28 and human hepatocellular carcinoma cell lines HepG(2) and SMMC7721 were used for the study. Anti-proliferative effect was measured by MTT assay, and apoptosis was determined by Hoechst-33258 staining, electronography and DNA fragmentation. The protein of cyclooxygenase-2 (COX-2) and Bcl-2 were detected by Western dot blotting. RESULTS: Sulindac could initiate growth inhibition and apoptosis of MKN45, MKN28, HepG(2) and SMMC7721 cells in a dose-and time-dependent manner. Growth inhibitory activity and apoptosis were more sensitive in HepG(2) cells than in SMMC7721 cells, MKN45 and MKN28 cells. After 24 hours incubation with sulindac at 2mmol x L(-1) and 4mmol x L(-1), the level of COX-2 and Bcl-2 protein were lowered in MKN45, SMMC7721 and HepG(2) cells but not in MKN28 cells. CONCLUSION: Sulindac could inhibit the growth of gastric cancer cells and HCC cells effectively in vitro by apoptosis induction, which was associated with regression of COX-2 and Bcl-2 expression. The growth inhibition and apoptosis of HCC cells were greater than that of human gastric cancer cells. The different effects of apoptosis in gastric cancer cells may be related to the differentiation of the cells.     

Downregulating sCLU Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Gemcitabine by Activating the Intrinsic Apoptosis Pathway

Purpose

The purpose of this study was to investigate whether the therapeutic activity of gemcitabine (GCB) in hepatocellular carcinoma (HCC) could be increased by the down-regulation of secretory clusterin (sCLU), a glycoprotein that is considered to play a cytoprotective role in the resistance to chemotherapy.

Methods

The expression of sCLU was detected in HCC tumor tissues and cell lines. A cell viability and apoptosis assay were performed in parental HCC cells or the same cells transfected with sCLU shRNA and treated with or without GCB. The potential downstream pathways were investigated using the Human Apoptosis RT² Profiler? PCR Array.

Results

The expression levels of sCLU in HCC tissues were significantly higher than in adjacent non-tumor liver tissues and were associated with the histological grade and transarterial chemoembolization. sCLU overexpression was also found in three HCC cell lines and hepatocytes. The depletion of sCLU synergistically increased GCB sensitivity in Bel7402 and SMMC7721 cells and induced cell apoptosis. Based on the PCR array analysis, sCLU depletion also resulted in the up-regulation of BNIP1, GADD45A, TNFRSF10A, and TRADD and down-regulation of AKT1 in Bel7402 and SMMC7721 cells compared with the parental controls. These results were further supported by a Western blot analysis, which showed increased GADD45a protein expression and the decreased expression of phosphorylated AKT. GADD45a overexpression also increased the sensitivity to GCB in the Bel7402 and SMMC7721 cells.

Conclusion

Targeting sCLU may be a useful method to enhance the cytotoxic effect of GCB in hepatocellular carcinoma.     

Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells

AIM： To study the expression and phosphorylation of extracellular signal-regulated kinase （ERK） i and ERK2 in multidrug resistant （MDR） hepatocellular carcinoma （HCC） cells.
METHODS： MDR HCC cell lines, HepG2/adriamycin （ADM） and SMMC7721/ADM, were developed by exposing parental cells to stepwise increasing concentrations of ADM. MTT assay was used to determine drug sensitivity. Flow cytometry was employed to analyze cell cycle distribution and measure cell P-glycoprotein （P-gp） and multidrug resistant protein 1 （MRP1） expression levels. ERK1 and ERK2 mRNA expression lev-ls were measured by quantitative real-time PCR （QRTPCR）. Expression and phosphorylation of ERK1 and ERK2 were analyzed by Western blot.
RESULTS： MTT assay showed that HepG2/ADM andSMMC7721/ADM were resistant not only to ADM, but also to multiple anticancer drugs. The P-gp expression was over 10-fold higher in HepG2/ADM cells than in HepG2 cells （8.92% ±0.22% vs 0.88% ± 0.05%, P 〈 0.001） and over 4-fold higher in SMMC7721/ADM cells than in SMMC7721 cells （7.37% ± 0.26% vs 1.74% ± 0.25%, P 〈 0.001）. However, the MRP1 expression was not significantly higher in HepG2/ADM and SMMC7721/ADM cells than in parental cells. In addition, the percentage of MDR HepG2/ADM and SMMC7721/ADM cells was significantly decreased in the G0/G1 phase and increased in the the S phase or G2/M phase. QRT-PCR analysis demonstrated that the ERK1 and ERK2 mRNA expression increased apparently in HepG2/ADM cells and decreased significantly in SMMC7721/ADM cells. Compared with the expression of parental cells, ERK1 and ERK2 protein expressions were markedly decreased in SMMC7721/ADM cells. However, ERK2 protein expression was markedly increased while ERK1 protein expression had no significant change in HepG2/ADM cells. Phosphorylation of ERK1 and ERK2 was markedly decreased in both HepG2/ADM and SMMC7721/ADM MDR cells.
CONCLUSION： ERK1 and ERK2 activities are downregulated in P-gp-mediated MDR HCC cells. ERK1 or ERK2 might be a potential drug target for circumventing MDR HCC cells,     

Human sulfatase‐1 inhibits the migration and proliferation of SMMC‐7721 hepatocellular carcinoma cells by downregulating the growth factor signaling

Aim: The human sulfatase‐1 (hSulf‐1) gene regulates the sulfation of heparan sulfate proteoglycans (HSPG) and suppresses tumorigenesis and angiogenesis by inhibiting several growth factor signaling pathways. Because the serine‐threonine protein kinase (AKT) and extracellular signal‐regulated kinase (ERK) signaling pathways are critical in cell survival, proliferation, migration and angiogenesis, the possible correlation between hSulf‐1 and AKT/ERK signaling in hepatocellular carcinoma (HCC) cells needs further exploration. Methods: Adenovirus Ad5‐hSulf1 carrying the hSulf‐1 gene, and vectors carrying hSulf‐1 shRNA, AKT shRNA and ERK shRNA were constructed and used to manipulate the expression of hSulf‐1, AKT and ERK in SMMC‐7721 cells. The scarification test, transwell and 3‐(4 5‐dimethylthiazol‐2‐yl)‐2 5‐diphenyltetrazolium bromide assays were used to examine the cellular migration and proliferation, and the expression of hSulf‐1 and signaling factors, including the total and phosphorylated AKT and ERK, was analyzed by western blot in SMMC‐7721 cells. Results: After infection with Ad5‐hSulf1, the expression of hSulf‐1 was increased with viral multiplicity of infection in SMMC‐7721 cells. Compared with the control adenovirus Ad5‐EGFP and blank control groups, cells in the Ad5‐hSulf1 group were showed that the phosphorylation of AKT and ERK was decreased. Meanwhile, the cell migration and cell viability were obviously suppressed. Conclusion: The expression of hSulf‐1 mediated by adenovirus in HCC cells could downregulate the activity of AKT and ERK signaling pathways, and inhibit HCC cell migration and proliferation. The hSulf‐1 gene may be considered as a candidate of antitumor factor for cancer gene therapy.     

XAF1基因重组腺病毒载体的构建及其在人肝癌细胞体内外的表达

目的利用携带35型腺病毒纤毛的嵌合型5型腺病毒载体系统Ad5/F35构建XAF1基因重组腺病毒,体内外感染人肝癌细胞SMMC7721并使XAF1基因有效表达。方法将真核表达质粒pcDNA3.1-XAF1和穿梭质粒pDC316用BamHⅠ和EcoRⅠ双酶切、筛选、测序获得重组穿梭质粒pDC316-XAF1。将测序正确的pDC316-XAF1和骨架质粒pBHG-fiber5/F35用Lipofectamine2000共转染HEK293细胞,进行细胞内同源重组,得到重组腺病毒Ad5/F35-XAF1。予终点稀释法测定重组腺病毒的感染滴度。用同样的方法得到携带增强型绿色荧光蛋白(EGFP)的报告病毒Ad5/F35-EGFP。建立人肝癌细胞株SMMC7721裸鼠移植瘤模型,将Ad5/F35-XAF1和Ad5/F35-EGFP重组腺病毒分别感染人肝癌细胞株SMMC7721和瘤内注射;荧光显微镜观察EGFP在细胞和移植瘤冰冻切片中的表达;RT-PCR和Westrenblot法检测XAF1的mRNA和蛋白在细胞和移植瘤组织的表达。结果重组腺病毒Ad5/F35-EGFP感染肝癌细胞和瘤内注射后,予荧光显微镜均可见细胞和冰冻切片中呈现绿色荧光;Ad5/F35-XAF1感染肝癌细胞和瘤内注射后,XAF1mRNA和蛋白表达均显著高于对照组和报告病毒组。结论成功构建重组腺病毒Ad5/F35-XAF1和Ad5/F35-EGFP。该腺病毒载体可携带目的基因在人肝癌细胞株SMMC7721体内和体外进行有效表达。     

siRNA沉默Cyclin E基因对肝癌HepG2、SMMC-7721和BEL-7402细胞增殖和侵袭能力的影响

目的:观察siRNA沉默Cyclin E基因表达对肝癌HepG2、SMMC-7721和BEL-7402细胞增殖和侵袭能力的影响.方法:构建2个靶向Cyclin E基因siRNA载体,转染人肝癌HepG2、SMMC-7721和BEL-7402细胞.RT-PCR、Western blot检测转染后HepG2、SMMC-7721和BEL-7402细胞Cyclin E基因mRNA和蛋白表达水平.CCK-8试验、软琼脂克隆形成实验检测HepG2、SMMC-7721和BEL-7402细胞增殖、克隆形成能力.流式细胞术、transwell试验分别检测HepG2、SMMC-7721和BEL-7402细胞周期和侵袭能力.结果:构建的2个Cyclin E基因siRNA载体插入序列与所设计序列均一致;转染HepG2、SMMC-7721和BEL-7402细胞后,干扰1组、干扰2组与空白对照组和阴性对照组比较,C y c l i n E m R N A和蛋白表达量均显著降低(P<0.05),细胞生长速度延缓,软琼脂细胞集落形成数、穿透细胞数均显著降低(P<0.05),S和G2/M期细胞比例减少,G0/G1期细胞比例增加.结论:沉默肝癌细胞Cyclin E表达水平,可有效抑制细胞生长、增殖和侵袭能力.     

Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells

BACKGROUND AND AIMS: Cyclooxygenase-2 (COX-2) is associated with carcinogenesis. The aim of this study was to investigate the expression of COX-2 in four hepatocellular carcinoma (HCC) cell lines, and evaluate the effect of a selective COX-2 inhibitor, meloxicam, in HepG2, a high COX-2 expressing cell line. METHODS: Expression of COX-2 was detected using RT-PCR, Western blotting and immunohistochemical analysis. Cell proliferation was measured using MTT assay. Cell cycle distribution was determined by flow cytometry. Apoptosis was detected with TUNEL method. Expression of proliferating cell nuclear antigen (PCNA), cell cycle regulatory proteins including cyclins A, B1, D1 and E, and apoptosis-related proteins including Fas, Fas ligand and Bcl-2 were examined using Western blotting. RESULTS: Cyclooxygenase-2 was intensely expressed in HepG2, HLE and BEL7402 cells, but weakly expressed in SMMC-7402 cells. Meloxicam suppressed proliferation of HepG2 cells in a dose- and time-dependent manner, resulting in cell cycle arrest in S phase and cell accumulation in G0/G1 phase. Expression of PCNA, cyclin A but not cyclin B1, cyclin D1 or cyclin E was down-regulated by meloxicam. Meloxicam also induced apoptosis of HepG2 cells, with increased expression of Fas ligand, but the expression of Fas and Bcl-2 was not affected by meloxicam treatment. CONCLUSIONS: The present study demonstrates that the specific COX-2 inhibitor meloxicam suppresses proliferation and induces apoptosis in HCC cells that express COX-2, suggesting that COX-2 inhibition may offer a novel chemopreventive and therapeutic approach for HCC.     

Hepatopoietin Cn suppresses apoptosis of human hepatocellular carcinoma cells by up-regulating myeloid cell leukemia-1

AIM:To investigate the role of hepatopoietin Cn(HPPCn) in apoptosis of hepatocellular carcinoma(HCC)cells and its mechanism. METHODS:Two human HCC cell lines,SMMC7721 and HepG2,were used in this study.Immunostaining, Western blotting and enzyme linked immunosorbent assay were conducted to identify the expression of HPPCn and the existence of an autocrine loop of HPPCn/ HPPCn receptor in SMMC7721 and HepG2.Apoptotic cells were detected using fluorescein isothiocyanate (FITC)-conjugated Annexin V and propidiu...     

Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis

AIM: To investigate the cyclooxygenase-2 (COX-2)expression level in human HepG2, Bel-7402 and SMMC-7721hepatoma cell lines and the molecular mechanism of COX-2 selective inhibitor celecoxib-induced cell growth inhibition and cell apoptosis.METHODS: Hepatoma cells were cultured and treated with celecoxib. Cell in situ hybridization (ISH) and immunocytochemistry were used to detect COX-2 mRNA and protein expression. Proliferating cell nuclear antigen and phosphorylated Akt were also detected by immunocytochemistry assay. Cell growth rates were assessed by 3-(4, 5-dimethylthiazol-2-yl-2, 5-diphenyltetrazolium (MTT) bromide colorimetric assay. Celecoxibinduced cell apoptosis was measured by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and flow cytometry (FCM). The phosphorylated Akt and activated fragments of caspase-9, caspase-3 were examined by Western blotting analysis.RESULTS: Increased COX-2 mRNA and protein expression were detected in all three hepatoma cell lines. Celecoxib could significantly inhibit cell growth and the inhibitory effect was in a dose- and time-dependent manner evidenced by MTr assays and morphological changes.The apoptotic index measured by TUNEL increased correspondingly with the increased concentration of celecoxib and the reaction time. With 50 μmol/L celecoxib treatment for 24 h, the apoptotic index of HepG2, BEL-7402and SMMC-7721 cells was 25.01±3.08%, 26.40±3.05%,and 30.60±2.89%, respectively. Western blotting analysis showed remarkable activation of caspase-9, caspase-3and dephosphorylation of Akt (Thr308). Immunocytochemistry also showed the reduction of PCNA expression and phosphorylation Akt (Thr308) after treatment with celecoxib.CONCLUSION: COX-2 mRNA and protein overexpression in HepG2, Bel-7402 and SMMC-7721 cell lines correlate with the increased cell growth rate. Celecoxib can inhibit proliferation and induce apoptosis of hepatoma cell strains in a dose- and time-dependent manner.     

MAGE-1修饰的树突状细胞体外诱导杀伤人肝癌细胞

目的通过观察肿瘤相关抗原基因MAGE-1转导的树突状细胞(dendritic     

反义寡核苷酸抑制肝癌血管内皮生长因子表达

目的 探讨不同序列的反义寡核苷酸对肝癌细胞血管内皮生长因子(VEGF)表达的抑制效果。 方法 SMMC7721细胞于正常氧和缺氧条件下培养24 h,观察缺氧对VEGF mRNA表达的影响;SMMC7721细胞接种于6孔板后,各加入不同的反义寡核苷酸(反帽子结构A06513、反翻译起始部位A06514、反第三外显子A06515、反翻译终止部位A06516和空白组),缺氧培养24 h,然后收集细胞提取总RNA并作逆转录聚合酶链反应分析,同时以管家基因GAPDH(3-磷酸甘油醛脱氢酶)表达为内对照。 结果 缺氧条件下,SMMC7721细胞VEGF mRNA表达明显增强,而有氧条件下未见表达;反义寡核苷酸具有明显抑制VEGF mRNA表达,和空白对照组相比,A06513、A06514、A06515及A06516的VEGF/GAPDH值分别为0.49±0.08、0.71±0.12、0.72±0.11及0.86±0.12(F=12.21,P<0.05)。帽子结构的反义基因表现最强的抑制作用(P<0.0 1)。 结论 与VEGF帽子结构作用的反义寡核苷酸,有望成为肝癌反义基因治疗的新选择。     

Up-regulation expression of MLC1 in human liver cancer tissue and enhanced SMMC7721 cell tumorigenesis in vivo and vitro

BACKGROUND/AIMS: We screened a novel gene MLC1 in human liver cancer tissue by differential display, and its cDNA full-length is 1600bp. The purpose of this study is to find expression of MLC1 gene in human liver cancer tissue and the affect to SMMC7721 cell tumorigenesis in vivo and vitro. METHODOLOGY: 250 cases of primary HCC tissue samples were studied for MLC1 mRNA and protein expression using RT-PCR, western blot, immunohistochemistry, MLC1 stable transfection into SMMC771, and SMMC7721 cells growth curve was analyzed by MTT method and SMMC7721 cells tumorigenesis in vivo. RESULTS: RT-PCR results showed that 98.1% (245/250) was MLC1 up-regulation expression, 1.9% (5/250) was MLC1 down-regulation (p<0.01). Immunohistochemistry showed that 97.2% (243/250) was MLC1 up-regulation expression, 2.8% (7/250) was down-regulation (p<0.01) in cancer tissue compared with paracancerous tissue (p<0.01). Western blotting results showed that 98.9% (247/250) was MLC1 up-regulation expression, 1.1% (3/250) was MLC1 down-regulation. Overexpression of MLC1 enhanced the growth of SMMC7721 cells compared with the control cells. pcDNA3.1-MLC1 cells accelerated tumor formation compared with pcDNA3.1. CONCLUSIONS: MLC1 gene showed up-regulation expression at both the mRNA and protein levels in HCC tissues and that MLC1 plays an important role in the growth of hepatoma cell SMMC7721 in vitro and vivo.     

miR-155在肝细胞癌中的表达及对肝癌细胞增殖的影响

目的:检测微小RNA-155(miR-155)在肝癌组织中的表达并分析其对肝癌细胞增殖和细胞凋亡的影响.方法:采用TagMan MGB探针法荧光定量P C R分析42例原发性肝癌及对应的癌旁组织miR-155的表达;利用miR-155反义寡核苷酸(ASO-miR-155)降低肝癌细胞HepG2和SMMC7721中miR-155的表达;利用MTT比色法检测肝癌细胞增殖的变化,并通过流式细胞技术检测肝癌细胞早期凋亡情况.结果:42例肝癌及癌旁组织标本中,miR-155在52%(22/42)肝癌组织中的表达明显高于癌旁组织(P<0.05);利用脂质体将ASO-miR-155转染肝癌细胞HepG2和SMMC7721后,miR-155的表达明显降低,肝癌细胞HepG2和SMMC7721生长受到明显抑制;并且细胞的早期凋亡明显增加.结论:miR-155在肝癌组织中过表达,降低其表达能明显抑制肝癌细胞的生长并诱导细胞早期凋亡,miR-155有可能成为肝癌治疗的新靶点.     

Inhibitory effect of endostatin expressed by human liver carcinoma SMMC7721 on endothelial cell proliferation in vitro

AIM: To construct a stable transfectant of human liver carcinoma cell line SMMC7721 that could secret human endostatin and to explore the effect of human endostatin expressed by the transfectant on endothelial cell proliferation. METHODS: Recombinant retroviral plasmid pLncx-Endo containing the cDNA for human endostatin gene together with rat albumin signal peptide was engineered and transferred into SMMC7721 cell by lipofectamine. After selection with G418, endostatin-transfected SMMC7721 cells were chosen and expanded. Immunohistochemical staining and Western blot were used to detect the expression of human endostatin in transfected SMMC7721 cells and its medium. The conditioned medium of endostatin-transfected and control SMMC7721 cells were collected to cultivate with human umbilical vein endothelial cells for 72 hours. The inhibitory effect of endostatin, expressed by transfected SMMC7721 cells, on endothelial proliferation in vitro was observed by using MTT assay. RESULTS: A 550 bp specific fragment of endostatin gene was detected from the PCR product of endostatin-transfected SMMC7721 cells. Immunohistochemistry and Western blot analysis confirmed the expression and secretion of foreign human endostatin protein by endostatin-transfected SMMC7721 cells. In vitro endothelial proliferation assay showed that 72 hours after cultivation with human umbilical vein endothelial cells, the optical density (OD) in group using the medium from endostatin-transfected SMMC7721 cells was 0.51 +/- 0.06, lower than that from RPMI 1640 group (0.98 +/- 0.09) or that from control plasmid pLncx-transfected SMMC7721 cells (0.88 +/- 0.11). The inhibitory rate for medium from endostatin-transfected SMMC7721 cells was 48%, significantly higher than that from empty plasmid pLncx-transfected SMMC7721 cells (10.2%, P<0.01). CONCLUSION: Human endostatin can be stably expressed by SMMC7721 cell transferred with human endostatin gene and its product can significantly inhibit the proliferation of human umbilical vein endothelial cell in vitro.     

腺病毒介导反义基质金属蛋白酶-2基因抑制肝癌生长的实验研究

目的 探讨携带反义基质金属蛋白酶-2（MMP2）基因的重组腺病毒（Ad-MMP2^AS）对人肝癌细胞株（Bel-7402）体外侵袭性和人肝癌动物模型生长的抑制作用。方法Ad-MMP2^AS感染人肝癌细胞Bel-7402后，用Boyden Chamber检测Ad-MMP2^AS对Bel-7402细胞降解人工基底膜Matrigel的抑制作用；Western blot和明胶酶谱分析测定Ad-MMP2^AS对Bel-7402细胞分泌MMP2的影响。将感染Ad-MMP2^AS的Bel-7402细胞接种于裸鼠皮下观察其成瘤能力；Ad-MMP2^AS瘤内注射，观察它对肝癌生长的抑制作用；肿瘤组织切片、HE染色观察瘤细胞生长情况。结果 Ad-MMP2^AS感染的Bel-7402细胞分泌MMP2被抑制、穿过Matrigel的Bel-7402细胞数下降52．05％、成瘤量下降3．3倍；瘤内注射Ad-MMP2^AS后瘤体生长抑制率为63．06％。结论 重组腺病毒介导的反义MMP2基因（Ad-MMP2^AS）能抑制肝癌的生长，对肝癌有治疗潜力。     

蛋白酶体β亚基4型对人肝癌SMMC7721细胞增殖存活的影响

目的旨在探讨蛋白酶体β亚基4型(PSMB4)对人肝癌SMMC7721细胞增殖存活的影响及其可能的机制。方法利用特异性短发夹RNA(shRNA)技术构建干扰PSMB4表达的SMMC7721实验组细胞;运用MTT、克隆形成实验检测细胞增殖的影响,流式细胞术检测细胞凋亡率的变化,Western Blot检测相关蛋白的表达变化。计量资料两组间比较采用独立样本t检验。结果成功构建了干扰PSMB4表达的SMMC7721实验组细胞(shRNA1:t=22.67,P<0.0001;shRNA2;t=30.88,P<0.0001;shRNA3:t=67.82,P<0.0001)。MTT实验显示第4天(0.4770±0.0135 vs 0.3237±0.0127,t=8.286,P=0.0012)、第5天(0.5893±0.0088 vs 0.3847±0.0090,t=16.220,P<0.0001)实验组细胞OD490值显著低于对照组。克隆形成实验显示细胞集落数显著减少。流式细胞术显示实验组细胞的早期凋亡率[(5.5570±0.2589)%vs(3.8870±0.3324)%,t=3.964,P=0.0166]、晚期凋亡率[(12.6300±0.4198)%vs(5.3100±0.3062)%,t=14.080,P=0.0001]及总凋亡率[(18.1800±0.6785)%vs(9.1970±0.6313)%,t=9.967,P=0.0006]均明显高于对照组,且干扰PSMB4表达的实验组细胞中核因子-κB亚基p65蛋白表达降低(0.8015±0.0120 vs 0.2841±0.0110,t=31.830,P<0.0001),核因子-κB抑制蛋白α表达增加(0.4816±0.0112 vs 0.6583±0.0142,t=9.774,P=0.0006)。结论干扰PSMB4表达可能通过抑制NF-κB信号通路,从而导致肝癌SMMC7721细胞的增殖存活能力下降。